Plasma Lipoprotein-associated Phospholipase A2 in Patients with Metabolic Syndrome and Carotid Atherosclerosis
2011

Lp-PLA2 Activity in Metabolic Syndrome and Carotid Atherosclerosis

Sample size: 188 publication Evidence: moderate

Author Information

Author(s): Gong Hui-ping, Du Yi-meng, Zhong Li-na, Dong Zhao-qiang, Wang Xin, Mao Yong-jun, Lu Qing-hua

Primary Institution: Second Hospital of Shandong University

Hypothesis

The study aimed to evaluate the potential role of Lp-PLA2 as a comprehensive marker of metabolic syndrome in individuals with and without carotid atherosclerosis.

Conclusion

Lp-PLA2 may be a modulating factor for carotid IMT via age and LDL-cholesterol, but is not an independent predictor in the pathophysiological process of carotid atherosclerosis in patients with MetS.

Supporting Evidence

  • Lp-PLA2 activity was significantly increased in MetS subgroups compared to controls.
  • Lp-PLA2 was higher in patients with carotid plaques than those without.
  • Age, LDL-cholesterol, and waist-hip ratio were significant determinants of Lp-PLA2 activity.

Takeaway

This study looked at a protein called Lp-PLA2 in people with metabolic syndrome and found that it might help understand heart problems, but it doesn't directly cause them.

Methodology

The study involved measuring Lp-PLA2 activity in 118 patients with metabolic syndrome and 70 healthy controls, using ELISA and ultrasound for carotid IMT.

Limitations

The study relied on single measurements of Lp-PLA2, which may not reflect true activity over time, and the influence of medications on Lp-PLA2 activity could not be eliminated.

Participant Demographics

118 patients with metabolic syndrome (53 men, 65 women, aged 32-71) and 70 age- and sex-matched healthy controls.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-511X-10-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication